+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides

Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides

Arthritis and Rheumatism 63(5): 1435-1445

To assess hemorrhagic cystitis and urinary tract cancer incidence and predictors in cyclophosphamide (CYC)-treated patients with systemic necrotizing vasculitis (SNV). The French Vasculitis Study Group database, which contains longitudinal data on SNV patients, was searched for urinary tract cancer and/or hemorrhagic cystitis occurrences in patients diagnosed as having Wegener's granulomatosis (WG), microscopic polyangiitis, Churg-Strauss syndrome, or polyarteritis nodosa. The observed incidence of urinary tract cancer was compared to the expected incidence in the general population by calculating standardized incidence ratios (SIRs). Relationships between urinary tract cancer and/or hemorrhagic cystitis and 10 variables, including CYC dosage and administration route, were investigated by survival analyses for a nested subgroup of patients for whom detailed information on CYC exposure was available. Among the 805 patients observed over 4,230 patient-years (mean followup 5.3 years), 22 cases of hemorrhagic cystitis and 7 of urinary tract cancer were identified in 27 patients. The SIRs for urinary tract cancer were 5.00 for all patients with SNV (P = 0.001) and 5.96 for patients with WG (P = 0.03). Based on 467 patients with detailed CYC information, cumulative CYC dose (hazard ratio [HR] for 10-gm increments 1.09; P = 0.03), ever-oral CYC administration (HR 5.50; P = 0.001), and WG (HR 2.96; P = 0.01) independently predicted urinary tract cancer and/or hemorrhagic cystitis. According to univariate analyses, smoking (ever) (HR 8.20; P = 0.02) and a prior hemorrhagic cystitis episode (HR 5.20; P = 0.046) significantly predicted urinary tract cancer. Our findings indicate that CYC treatment of SNV is associated with a 5-fold higher risk of developing urinary tract cancer. Urotoxicity risk in SNV is associated with the cumulative CYC dose and its oral administration, and might be higher in WG.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 053789105

Download citation: RISBibTeXText

PMID: 21337321

DOI: 10.1002/art.30296

Related references

Factors associated with major cardiovascular events in patients with systemic necrotizing vasculitides: results of a longterm followup study. Journal of Rheumatology 41(4): 723-729, 2014

Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis and Rheumatology 67(4): 1117-1127, 2015

Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz. Germs 5(3): 83-91, 2015

Predictors of major adverse cardiac events in patients treated with rotational atherectomy. European Heart Journal 21(Abstract Suppl.): 645, August-September, 2000

Systemic necrotizing vasculitides in Turkey: a comparative analysis of 40 consecutive patients. Rheumatology International 26(1): 16-20, 2004

Re-evaluation of 129 patients with systemic necrotizing vasculitides by using classification algorithm according to consensus methodology. Clinical Rheumatology 31(2): 325-328, 2012

Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. American Journal of Epidemiology 176(8): 708-719, 2012

High incidence of discontinuations due to adverse events in patients treated with ceftaroline. PharmacoTherapy 34(7): 758-763, 2014

Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors. British Journal of Haematology 136(6): 800-805, 2007

Two cases of necrotizing scleritis treated by systemic cyclophosphamide. Rinsho Ganka 59(3): 345-348, 2005

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. Journal of Clinical Endocrinology and Metabolism 101(11): 4431-4439, 2016

Systemic adverse events following intraarticular corticosteroid injections for the treatment of juvenile idiopathic arthritis: two patients with dermatologic adverse events and review of the literature. Seminars in Arthritis and Rheumatism 43(1): 71-76, 2013

Incidence of neuropsychiatric adverse events in influenza patients treated with oseltamivir or no antiviral treatment. International Journal of Clinical Practice 63(4): 596-605, 2009

The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada. Cmaj 170(11): 1678-1686, 2004

Cyclophosphamide in systemic lupus erythematosus Cumulative dose and adverse events. Lupus 10(Suppl. 1): S104, 2001